Bristol-Myers Squibb Company (0R1F.IL)

43.83 -0.39 (-0.89%) At close: 07:13PM BST

Bristol-Myers Squibb Company

430 East 29th Street
14th Floor
New York, NY 10016
United States
212 546 4000
https://www.bms.com

Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full-time employees: 34,300

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Giovanni Caforio M.D.	Chairman & CEO	5.76M	N/A	1965
Mr. David V. Elkins	Exec. VP & CFO	2.72M	2.83M	1968
Dr. Christopher S. Boerner Ph.D.	Exec. VP, COO & Director	2.62M	N/A	1971
Ms. Sandra Leung Esq.	Exec. VP & Gen. Counsel	2.66M	N/A	1961
Mr. Greg Meyers	Exec. VP and Chief Digital & Technology Officer	N/A	N/A	1973
Mr. Timothy Power	VP & Head of Investor Relations	N/A	N/A	N/A
Ms. Ann M. Powell Judge	Exec. VP & Chief HR Officer	N/A	N/A	1966
Dr. Fouad Namouni M.D.	Head of Oncology Devel.	N/A	N/A	1969
Mr. Samit Hirawat M.D.	Exec. VP & Chief Medical Officer of Drug Devel.	N/A	N/A	1969
Dr. Joseph J. Eiden Jr.	Head of Medical Affairs	N/A	N/A	1949

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Corporate governance

Bristol-Myers Squibb Company’s ISS governance QualityScore as of 1 October 2023 is 2. The pillar scores are Audit: 4; Board: 5; Shareholder rights: 2; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.